Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

TSE:HMMJ

Horizon's Medical Marijuana (HMMJ.TO)

7.22
-0.06 (0.82%)
as of Jun 15, 2026, 7:59:40 pm Market Open.
114 watching
0
Investor Insights
star iconJun 15, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Horizon Medical Marijuana (HMMJ-T) has captured the attention of several experts, particularly regarding its potential for significant growth. There is optimism surrounding the possibility of new banking legislation that could greatly affect the company's fortunes, with some experts noting strong bipartisan support for such a change. The stock is characterized by high volatility, suggesting that it can experience rapid changes in price, which may present both risks and opportunities for investors. The consensus is that Horizon Medical Marijuana could be a standout performer, with the potential to become a multi-bagger investment, possibly offering returns that could multiply by 2, 4, 5, or even 10 times its current value. This combination of legislative prospects and market dynamics makes it a compelling option for investors seeking substantial gains in the marijuana sector.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
APHA,APHA
BUY

HMMJ vs. HMUS. A monstrous opportunity, but you're going to suffer volatility. Go slow, get in over time, and keep it to a smaller proportion of your portfolio. Market weighted. The US exposure is to companies operating legally, and there can't be any recreational use. With HMUS, you're tapping into a bigger market. For example, Charlotte's Web is planning to sell CBD infused products through Kroeger. This scale dwarfs the whole Canadian market. Valuations are high because of the growth potential. If you're a marijuana investing aficionado, you'd want to own both.

COMMENT
Any vice will do well, and so will this. Horizon makes great ETFs. That said, ETF's aren't always the best. Instead of buying the weed basket, buy the leader--Canopy.
DON'T BUY
Companies on this don't have any earnings. With out earnings he doesn't want it.
COMMENT
How does this pay a yield if weed stocks don't? It does pay a dividend, perhaps from capital gains from buying and selling those weed stocks within the ETF. He doesn't think cannabis will be an exciting industry, but will wind up like the liquor business.
BUY ON WEAKNESS
This has the potential for massive growth in 20 years considering the medical applications of cannabis, but this space also has massive volatility. Buy during large declines and tiptoe in. Society is in the process of accepting marijuana. This is a sea change now.
COMMENT
There is some downside pressure on HMMJ-T. At the $14 or $17 range there is resistance. Who knows what the effect would be if the government changes in October. [Caller asked about TLRY] He sees $34 as a target on TLRY-T as there is nothing to hold it higher.
WAIT
X-dividend date coming up. After the next economic downturn, this will be a sector to invest in and forget it for a decade. At this point he does not see it goes above the recent highs. Don't invest in it now. You might trade it.
COMMENT
This has attracted A LOT of interest, but inflows into cannabis have plateaud. There's lots of speculation and uncertainty, though it's an interesting space. Definitely, cannabis is not a core holding of his. It's typically to see extreme moves in this ETF and sector. This charges an 0.87% MER. Also consider the smaller SEED-T.
DON'T BUY
Exercise caution. Big move in the underlying companies, so you're always susceptible to a pullback. Shift focus more to the US, where you can get more reasonable valuations. US market is 10x what Canada's is. Money spirals in, and out, of these ETFs. Tough to justify valuations in Canada right now. It's a psychology trade.
COMMENT
He is not an expert in cannabis. There will be real industry going forward and some companies will prosper in the long term. The valuations still remain excessive. If he were to participate it would be with Canopy Growth as they have a connection with Constellation Brands in the US.
BUY ON WEAKNESS
Cannabis. Momentum was stalling in September. There is a short term bounce but there will be choppiness in the short term. He would pick away at these names during this period. The longer term trend is up.
COMMENT

Short selling: He has not done much short selling in this space. He tends to be long. If he was going to do it, this would be the vehicle to do it with. There would not be any M&A risk.

RISKY

It is been a ridiculously volatile space. The whole sector is very expensive. Very early inning of the industry. This is a decent way to dip your toe in the sector. Volatile above and beyond what normal equity markets are.

DON'T BUY

It is a great play on the space. He noticed that in the last few months there has been a lack of new capital going into it so people must be trying to pick a winner. He cautions that the space is going to be very volatile over the next 6 months.

BUY

He is into macro trends and themes. So, this doesn’t fit his strategy. But he thinks it is a good ETF. It pays a dividend because it lends shares he thinks.

Showing 16 to 30 of 61 entries